Tecarfarin

Summary

Tecarfarin (CHEMBL2105664) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 5
• Chemistry: 460.3 Da · C21H14F6O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105664
Name	Tecarfarin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	54718618
Molecular formula	C21H14F6O5
Molecular weight	460.3
InChIKey	QFLNTQDOVCLQKW-UHFFFAOYSA-N

SMILES: CC(C(F)(F)F)(C(F)(F)F)OC(=O)C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O

IUPAC name: (1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate

Also known as: ATI-5923, Tecarfarin, Tecarfarina, Tecarfarine, TECARFARIN

Parent form; salt/anhydrous children: CHEMBL2105676

Patent coverage: 26 distinct patent families (64 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 47 (73%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	2
PHASE2/PHASE3	1
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00691470	PHASE2/PHASE3	UNKNOWN	Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
NCT02522221	PHASE3	UNKNOWN	Tecarfarin Anti-Coagulation Trial (TACT)
NCT00431782	PHASE2	COMPLETED	Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation
NCT03652779	PHASE1	COMPLETED	A Study to Evaluate the Safety and Tolerability of Tecarfarin in Healthy Chinese Volunteers
NCT04627116	PHASE1	UNKNOWN	An Ascending, Multiple-Dose, Safety and Tolerability Study of Tecarfarin in Healthy Chinese Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).